- Clinical Pipeline
- Guadecitabine (SGI-110) DNMT inhibitor (Hematological Malignancies and Solid Tumors)
- Beroterkib (ASTX029) Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
- Oral Decitabine and Cedazuridine (ASTX727) (Hematological Malignancies)
- ASTX660 Dual IAP Antagonist (Solid Tumors & Lymphomas)
- ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
- Partnered Products and Programs
- Kisqali®(ribociclib) CDK4/6 inhibitor (Oncology)
- Balversa® (erdafitinib) FGFr inhibitor (Oncology)
- Truqap™ PKB/Akt Inhibitor (Oncology)
- Multiple Targets and Therapeutic Areas
- Pyramid™ Discovery Platform
- Oncology and CNS Discovery
- Sustaining Innovation
Below is our pipeline of investigational compounds that are currently in various stages of clinical development.
For more information on the pipeline of investigational compounds generated by Astex that are currently in clinical development at Taiho Oncology Inc., please follow the link here
For more information on the pipeline of products being developed globally at Otsuka, please follow the link here
Phase 1 | Phase 2 | Phase 3 |
---|
Tolinapant (ASTX660)
Antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP) (T-cell Lymphomas)
. | . |
Beroterkib (ASTX029)
Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
. |
ASTX295
Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
. |